Medicinal chemistry: an effect of a desolvation penalty of an amide group in the development of kinase inhibitors
- 55 Downloads
An analysis of VEGFR-2 conformers from the PDB allowed us to identify an unused salt bridge containing pocket (SBCP) suitably positioned over an AAZ ligand (PDB: 1Y6A). The SBCP consists of Lys866, Glu883 and Phe1045. The closest distance (4.5 Å) between AAZ and the centre of the SBCP has para-carbon from the AAZ internal phenyl ring. This is a bit longer as required for a simple substitution on AAZ to interact with SBCP. To investigate ligand–SBCP interaction, we extended the structure of AAZ by an insertion of an amide group between an oxazole and its aromatic substituent. This allowed moving the internal Ph ring of the carboxamide ligand closer to the SBCP. Promising predictions (poses and scores) were determined for such novel ligands by the Glide (Schrödinger) and the Dock (UCSF) software. Fifteen novel carboxamides 4(a–j,l–p) were prepared and screened. Surprisingly, their enzymatic activities are much lower (IC50: 7.6–437 μM) as expected than the AAZ ligand (22 nM). To explain this discrepancy, we hypothesized that high solvation energy could be a main reason for the penalty that ligands have to pay by their binding to the target. Therefore, 11 additional AAZ analogues possessing modified or replaced amide group by less solvated substituents 4(q–r); 5(a–e), 7(a–b), 9, 10 were developed. A correlation between IC50 activities and calculated solvation energies clearly supported our hypothesis. The ligands possessing less solvated group (instead of the –CONH–) were more powerful VEGFR2 TK inhibitors and vice versa. This conclusion was supported also by a significance of hydrophobic enclosure descriptor in the identified QSAR models. We can conclude that the insertion of a highly solvated extension fragment (e.g. the amide group) in the ligand should be carefully considered especially when this group will act in a hydrophobic part of a protein without forming additional interaction(s). Otherwise, the desolvation penalty of an inserted group could be a limiting factor for a ligand activity.
KeywordsVEGFR-2 TK SBCP pocket Tyrosine kinase inhibitors Amide group insertion Energy of solvation Desolvation penalty 2-(Arylamino)oxazole-5-carboxamide N,5-Diaryloxazol-2-amine QSAR
This research was supported by Biomagi, Ltd. (discovery of the SBCP pocket, an idea of an amide group insertion, Dock UCSF design of inhibitors), JD (a solvation hypothesis and calculations), VEGA 1/0670/18, VEGA 2/0064/15 (QSAR) and ITMS 26240220086 (HPLC MS). We are grateful to Mgr. Juraj Filo, PhD., for the measurement of NMR spectra.
- Ferrara N (2004) Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9(Suppl1):2–10. http://www.ncbi.nlm.nih.gov/pubmed/15178810. Accessed 30 May 2017
- Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749. https://doi.org/10.1021/jm0306430 CrossRefGoogle Scholar
- Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177–6196. https://doi.org/10.1021/jm051256o CrossRefGoogle Scholar
- Glide, version 7.0, (2016)Google Scholar
- Harris PA, Cheung M, Hunter RN, Brown ML, Veal JM, Nolte RT, Wang L, Liu W, Crosby RM, Johnson JH, Epperly AH, Kumar R, Luttrell DK, Stafford JA (2005) Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem 48:1610–1619. https://doi.org/10.1021/jm049538w CrossRefGoogle Scholar
- Lintnerová L, García-Caballero M, Gregáň F, Melicherčík M, Quesada AR, Dobiaš J, Lác J, Sališová M, Boháč A (2014) A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex—Medicinal chemistry consequences of a TKs analysis. Eur J Med Chem 72:146–159. https://doi.org/10.1016/j.ejmech.2013.11.023 CrossRefGoogle Scholar
- ProQuinase GmbH. https://www.proqinase.com/. Accessed 8 Mar 2018
- Reaction Biology Corp. www.reactionbiology.com. Accessed 8 Mar 2018
- Waltenberger J, Claessonwelsh L, Siegbahn A, Shibuya M, Heldin C (1994) Different signal-transduction properties of Kdr and Flt1, 2 receptors for vascular endothelial growth-factor. J Biol Chem 269:26988–26995. http://www.jbc.org/content/269/43/26988.long. Accessed 8 Mar 2018